Sales & Earnings In Brief: Merck, Glaxo, Prestige Brands, Teva, Mead Johnson
This article was originally published in The Tan Sheet
Merck slates consumer unit decision for 2014; Glaxo consumer up 4% on oral care sales; Prestige Brands income plummets, Teva OTC growth continues; Mead Johnson rides Asian market growth; Church & Dwight boosts gummy marketing; and USANA builds on incentive program.
You may also be interested in...
GNC hires Josh Burris as chief US officer; Clasado BioSciences adds Bellchambers as commercial director; and Barentz plans expansion with Cinven investment.
The House passage of a Democratic bill authorizing the federal government to negotiate drug prices in Medicare has sharpened the debate over how prices feed innovation, but the underlying policy stands little chance of being enacted without a Democratic wave in the next election. Pink Sheet's table highlights the key provisions of HR 3 and other pending pricing legislation.